Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025 (Katherine Davis/Axios)
Katherine Davis / Axios : Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from $1.6B after its $365M Series D in May 2025 — Precision oncology biotech Pathos AI said Friday it raised a $237 million Series E round at a $3 billion post-money valuation.
Sources
Related
- OpenAI makes Decisions API, its Jev competitor, generally available with new voice and visual modalities, at $0.10/1M input tokens and no output-token charges (Tim Fernholz/TechCrunch) OCT 23, 2026
- OpenAI Targets $1.25 Trillion Valuation in New Funding Round OCT 23, 2026
- An interview with Intel's leadership, including CTO Pushkar Ranade, on AI chip demand, lessons from 10nm, whether Intel can catch up to TSMC, Terafab, and more (Dwarkesh Patel/Dwarkesh Podcast) OCT 23, 2026
- Sources: Anthropic and London-based PE firm Hg agree to launch a consultancy by the end of 2026 to embed AI consultants and engineers into European businesses (Financial Times) OCT 23, 2026
- China APT Uses AI Pentest Tool Artex in ConnectWise Attacks OCT 23, 2026